Upgrade to ChromeUpgrade to FirefoxUpgrade to Internet ExplorerUpgrade to Safari

Meet the Management Team

Speak to our team

Contact us today to see how we can help

Contact Us

Led by Phil McEwan and Jason Gordon, and supported by our experienced teams of Senior Managers and Principals, HEOR Ltd comprises of over 50 researchers, analysts and writers.

We provide a supportive culture focused on individual’s development and satisfaction; consequently, we have a high rate of staff tenure. Our staffing model is designed to recruit and retain staff that provide a powerful mix of technical and research excellence, commercial awareness, and second to none deliverables. Our rationale is to have in place the resources required to deliver exceptional quality and innovation that promotes the appropriate use of technologies and maximises their commercial opportunity.

Directors

Senior Managers

Our Senior Management is made up of Ian Jacob (Health Economics) and Daniel Sugrue (Medical Writing).

Research Analysts

Modelling the natural history of disease and the impact of therapeutic interventions is at the core of our research activities. Our research analysts, led by Hayley Bennett-WiltonTom Ward and Oliver Darlington, develop, adapt and validate the full range of health economic models, from natural history disease models through to cost-effectiveness and budget impact models.

Medical Writers

Our team of medical writers is headed by Principal Medical Writer, Beverley Jones.  Our writing group have a wealth of experience in health technology assessment and publication developments providing insightful, scientific output.

Statisticians

Providing conventional and modern statistical analytics to clinical trial and real-world data and evidence synthesis; our team of statisticians and data scientists are led by Michael Hurst.

Market Access and Reimbursement

Chronic hepatitis C virus (HCV) infection is associated with significant morbidity and mortality. The global prevalence of HCV infection has been estimated at 1.6% (1.3–2.1%), equivalent to 115 (92–149) million individuals. Whereas rates of infection are decreasing in the developed world, HCV related liver disease is expected to increase due to the latent nature of early infection and the significant number of undiagnosed cases.

View Case Study

Contact us today to see how we can help

Contact Us